Disclosed positions

Estimated from their latest filings — positions may have changed since

$4.58M

combined est. value

Stock	Shares	Price	Value	Weight	As of
RPRXRoyalty Pharma plc	79,181	$57.80	$4.58M	100%	2026-06-30
REGNREGENERON PHARMACEUTICALS, INC.	1,703	—	—		2026-01-07

RPRX

Royalty Pharma plc

$4.58M

79,181 sh

REGN

REGENERON PHARMACEUTICALS, INC.

—

1,703 sh

All filings on record

Every Form 4 transaction we track for this filer

all 10buys 0sells 2

Stock	Transaction	Date	~6mo later
RPRXRoyalty Pharma plc	Grant $37.5K · 689 sh	2026-06-30	—
REGNREGENERON PHARMACEUTICALS, INC.	Sell $1.20M · 1,500 sh	2026-01-07	—
REGNREGENERON PHARMACEUTICALS, INC.	Exercise $561.2K · 1,500 sh	2026-01-07	—
CDTXCidara Therapeutics, Inc.	Return $3.3K · 15 sh	2026-01-07	—
REGNREGENERON PHARMACEUTICALS, INC.	Grant — · 155 sh	2026-01-02	—
RPRXRoyalty Pharma plc	Grant $37.5K · 967 sh	2025-12-31	—
REGNREGENERON PHARMACEUTICALS, INC.	Sell $570.0K · 760 sh	2025-11-20	—
REGNREGENERON PHARMACEUTICALS, INC.	Exercise $282.3K · 760 sh	2025-11-20	—
RPRXRoyalty Pharma plc	Grant $37.5K · 1,047 sh	2025-09-30	—
RPRXRoyalty Pharma plc	Grant $37.5K · 1,064 sh	2025-06-30	—

RPRXGrant

2026-06-30 · Royalty Pharma plc

$37.5K

—

REGNSell

2026-01-07 · REGENERON PHARMACEUTICALS, INC.

$1.20M

—

REGNExercise

2026-01-07 · REGENERON PHARMACEUTICALS, INC.

$561.2K

—

CDTXReturn

2026-01-07 · Cidara Therapeutics, Inc.

$3.3K

—

REGNGrant

2026-01-02 · REGENERON PHARMACEUTICALS, INC.

155

—

RPRXGrant

2025-12-31 · Royalty Pharma plc

$37.5K

—

REGNSell

2025-11-20 · REGENERON PHARMACEUTICALS, INC.

$570.0K

—

REGNExercise

2025-11-20 · REGENERON PHARMACEUTICALS, INC.

$282.3K

—

RPRXGrant

2025-09-30 · Royalty Pharma plc

$37.5K

—

RPRXGrant

2025-06-30 · Royalty Pharma plc

$37.5K

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.